DOCSLIB.ORG

Progressive Familial Intrahepatic Cholestasis FACT SHEET

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Progressive Familial Intrahepatic Cholestasis FACT SHEET PFIC Progressive Familial Intrahepatic Cholestasis FACT SHEET About PFIC Progressive familial intrahepatic cholestasis (PFIC) is a group of rare genetic liver diseases that affects children globally.1 Bile acids accumulate in the liver and bloodstream, causing progressive damage. In many cases, patients diagnosed with PFIC experience end-stage liver disease by age 10.2 A serious consequence of PFIC is severe itching that can lead to sleepless nights for the whole family. If left unprotected, babies may even scratch through their skin, causing bleeding, scabs, and wounds. Images provided with consent from families to illustrate pruritus. PFIC Types Doctors and researchers are still working to understand the different types of PFIC. Three main genes are involved in the spectrum of PFIC, each of which is necessary for bile acid transport out of the liver. As the result of a defect in one of the genes, bile acids accumulate in the liver and bloodstream, causing progressive symptoms within and, sometimes, outside the liver. PFIC is a spectrum of disorders caused by mutations on different genes—ATP8B1, ABCB11 and ABCB4—that have similar loci and affect bile acid metabolism. The mutations result in variability in terms of severity, age of onset, and presence of extrahepatic manifestations, such as nutrient malabsorption, growth delays, gastrointestinal problems, and risk of pancreatitis and liver cancer. These are currently the most commonly recognized forms: PFIC1 (FIC 1 deficiency). Jaundice and pruritus are usually the first symptoms. Patients may also experience diarrhea, slow growth, pancreatitis and hearing problems. Wide range of severity. PFIC 2 (BSEP deficiency). Pruritus can be severe. Growth is slowed. Cirrhosis often occurs by age 10. Fatty stools are common. There is a risk of liver cancer. PFIC3 (MDR3 deficiency). Pruritus tends to be milder. Gallstones and hypertension are common. Wide range of severity. BRIC. Benign recurrent intrahepatic cholestasis, associated with similar genetic mutations as PFIC 1 or PFIC 2 is a form of PFIC that may not be diagnosed until later in life. Symptoms may be triggered without warning and continue for weeks or months before subsiding. This may also present as intrahepatic cholestasis of pregnancy. Signs and Symptoms Treatment Limited to PFIC signs and symptoms may vary by person. Surgical Interventions Here are some that parents and physicians have There is currently no approved pharmacologic described: treatment for PFIC. When itching is severe or when Yellowing of the skin (jaundice). This may be one liver disease progresses, families may consider of the earliest signs of PFIC. surgical options. Severe itching (pruritus). Severe itching is the Biliary diversion. There are two ways to perform most disruptive symptom in the day-to-day lives a biliary diversion, which are partial internal biliary of children with PFIC. diversion (PIBD) and partial external biliary diversion (PEBD). For patients with PFIC, PEBD is the more Vitamin malabsorption and nutritional common surgical procedure wherein bile is diverted problems. People with PFIC have difficulty absorbing fats and fat-soluble vitamins, such as out through the abdominal wall and collected in an vitamins A, D, E and K, potentially causing poor ostomy bag outside the body. PEBD may provide growth.3 Some parents also report a weakened relief for months or even years, but may not be a 4 immune system. permanent solution. Liver transplantation may Liver problems. The accumulation of bile acids Liver transplantation. damages the liver over time.3 Many people with be an option for some patients who experience 5,6 PFIC will suffer from end-stage liver disease by the progressing liver disease or severe itching. Like all age of 10.1 Only one third of people with PFIC reach major surgeries, it has significant risks. Even when it adulthood with their native liver. is successful, it requires the patient to receive life- long immunosuppressive therapy to prevent the Other signs and symptoms. Some patients body from rejecting the new liver. experience enlarged liver and spleen, diarrhea, hemorrhage (bleeding), high blood pressure, gastrointestinal bleeding, pale stools, pancreatitis, gallstones, and rickets. Diagnosing PFIC For more information and resources, PFIC is often diagnosed in infancy. Parents may visit www.PFICvoices.com take their baby to the hospital because of jaundice or itching. Doctors will try to rule out other, more common causes first. A PFIC diagnosis can be About Albireo confirmed with a genetic test. Albireo is committed to this devastating disease. PFIC is an autosomal recessive disorder. This means supporting people with The company is focused that a child must inherit the same affected gene PFIC, their families, and on the development of from both parents for the disease to be present. healthcare providers novel bile acid modulators A child who only inherits the affected gene from one with resources to better to treat rare pediatric liver parent will be a “carrier” but will not have understand and manage diseases, such as PFIC. the disease. References 1. Davit-Spraul, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis. 2009;4:1. 2. Mehl A, Bohorquez H, Serrano MS, et al. Liver transplantation and the management of progressive familial intrahepatic cholestasis in children. World J Transplant. 2016;6(2):278-90. 3. Srivastava A. Progressive Familial Intrahepatic Cholestasis. J Clin Exp Hepatol 2014;4:25-36. 4. Bull LN, Pawlikowska L, Strautnieks S, et al. Outcomes of surgical management of familial intrahepatic cholestasis 1 and bile salt export protein deficiencies. Hepatol Commun 2018;2(5):515-528. 5. Alissa FT, Jaffe R, Shneider BL. Update on progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr. 2008;46(3):241-52. 6. Pawlikowska L, Strautnieks S, Jankowska I, et al. Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol. 2010;53(1):170-8. ©2020 Albireo Pharma, Inc. All rights reserved. PFIC VOICES and the PFIC VOICES logo are registered marks of Albireo Pharma, Inc. or its affiliates. PFIC-0120.
Load more

Recommended publications
  • A Drug-Induced Cholestatic Pattern
    Review articles Hepatotoxicity: A Drug-Induced Cholestatic Pattern Laura Morales M.,1 Natalia Vélez L.,1 Octavio Germán Muñoz M., MD.2 1 Medical Student in the Faculty of Medicine and Abstract the Gastrohepatology Group at the Universidad de Antioquia in Medellín, Colombia Although drug induced liver disease is a rare condition, it explains 40% to 50% of all cases of acute liver 2 Internist and Hepatologist at the Hospital Pablo failure. In 20% to 40% of the cases, the pattern is cholestatic and is caused by inhibition of the transporters Tobon Uribe and in the Gastrohepatology Group at that regulate bile synthesis. This reduction in activity is directly or indirectly mediated by drugs and their me- the Universidad de Antioquia in Medellín, Colombia tabolites and/or by genetic polymorphisms and other risk factors of the patient. Its manifestations range from ......................................... biochemical alterations in the absence of symptoms to acute liver failure and chronic liver damage. Received: 30-01-15 Although there is no absolute test or marker for diagnosis of this disease, scales and algorithms have Accepted: 26-01-16 been developed to assess the likelihood of cholestatic drug induced liver disease. Other types of evidence are not routinely used because of their complexity and cost. Diagnosis is primarily based on exclusion using circumstantial evidence. Cholestatic drug induced liver disease has better overall survival rates than other patters, but there are higher risks of developing chronic liver disease. In most cases, the patient’s condition improves when the drug responsible for the damage is removed. Hemodialysis and transplantation should be considered only for selected cases.
    [Show full text]
  • A Rare Hepatic Manifestation of Systemic Lupus Erythematosus
    Cholestatic hepatitis in SLE Cholestatichepatitis:ararehepaticmanifestationof systemiclupuserythematosus WHChow,MSLam,WKKwan,WFNg Systemic lupus erythematosus is a multi-system inflammatory disease. The clinical manifestations are diverse. Hepatic manifestation is a rarely seen complication of systemic lupus erythematosus. We report a case of complication of systemic lupus erythematosus presenting as cholestatic hepatitis in a 56-year- old Chinese woman. The cholestatic hepatitis progressed as part of the lupus activity and responded to steroid therapy. HKMJ 1997;3:331-4 Key words: Hepatitis; Cholestasis; Lupus erythematosus, systemic; Liver Introduction of body weight and had had a poor appetite. She was a non-drinker and had no long term drug history. Systemic lupus erythematosus (SLE) is a multi- system inflammatory disease associated with the A general examination showed her to be jaundiced, development of auto-antibodies to a variety of self- pale, and dyspnoeic with an elevated body tempera- antigens. The clinical manifestations of SLE are ture of 38.2°C. Chest examination demonstrated coarse diverse. In 1982, the American Rheumatism Associa- crackles heard over both lung fields. Other parts of tion (ARA) published revised criteria for the classifi- the examination were unremarkable. There was 2+ cation of SLE.1 For a diagnosis of SLE, individuals proteinuria in the mid-stream urine but the culture should have four or more of the following features: for organisms was negative. Investigations revealed a malar rash, discoid rash, photosensitivity, oral ulcers, normochromic, normocytic anaemia (haemoglobin 9.4 non-erosive arthritis, pleuritis or pericarditis, renal g/dL [normal range, 11.5-15.5 g/dL]) with normal disorder, seizures or psychosis, haematological white cell and differential counts.
    [Show full text]
  • Primary Biliary Cholangitis: a Brief Overview Justin S
    REVIEW Primary Biliary Cholangitis: A Brief Overview Justin S. Louie,* Sirisha Grandhe,* Karen Matsukuma,† and Christopher L. Bowlus* Primary biliary cholangitis (PBC), previously referred to supported by the higher concordance of PBC in monozy- as primary biliary cirrhosis, is the most common chronic gotic compared with dizygotic twins.4 In addition, certain cholestatic autoimmune disease affecting adults in the human leukocyte antigen haplotypes have been associ- United States.1 It is characterized by a hallmark serologic ated with PBC, as well as variants at loci along the inter- signature, antimitochondrial antibody (AMA), and specific leukin-12 (IL-12) immunoregulatory pathway (IL-12A and bile duct pathology with progressive intrahepatic duct de- IL-12RB2 loci).5 struction leading to cholestasis. PBC is potentially fatal and can have both intrahepatic and extrahepatic complications. PATHOGENESIS EPIDEMIOLOGY The primary disease mechanism in PBC is thought to be T cell lymphocyte–mediated injury against intralobu- PBC affects all races and ethnicities; however, it is best lar biliary epithelial cells. This causes progressive destruc- studied in the Caucasian population. The condition pre- tion and eventual disappearance of the intralobular bile dominantly affects women older than 40 years, with a ducts. Molecular mimicry has been proposed as the ini- female/male ratio of 9:1.2 Although the incidence of PBC tiating event in the loss of tolerance primarily to mito- appears to be stable, the overall prevalence of the disease chondrial pyruvate dehydrogenase complex, E2, during is increasing.3 An individual’s genetic susceptibility, epige- which exogenous antigens evoke an immune response netic factors, and certain environmental triggers seem to that recognizes an endogenous (self) antigen inciting an play important roles.
    [Show full text]
  • Progress Report Cholestasis and Lesions of the Biliary Tract in Chronic Pancreatitis
    Gut: first published as 10.1136/gut.19.9.851 on 1 September 1978. Downloaded from Gut, 1978, 19, 851-857 Progress report Cholestasis and lesions of the biliary tract in chronic pancreatitis The occurrence of jaundice in the course of chronic pancreatitis has been recognised since the 19th century" 2. But in the early papers it is uncertain whether the cases were due to acute, acute relapsing, or to chronic pan- creatitis, or even to pancreatic cancer associated with pancreatitis or benign ampullary stenosis. With the introduction of endoscopic retrograde cholangiopancreato- graphy (ERCP), there has been a renewed interest in the biliary complica- tions of chronic pancreatitis (CP). However, papers published recently by endoscopists have generally neglected the cholangiographic aspect of the lesions and are less precise and less well documented than papers published just after the second world war, following the introduction of manometric cholangiography3-5. Furthermore, the description of obstructive jaundice due to chronic pancreatitis, classical 20 years ago, seems to have been forgotten until the recent papers. Radiological aspects of bile ducts in chronic pancreatitis http://gut.bmj.com/ If one limits the subject to primary diseases of the pancreas, particularly chronic calcifying pancreatitis (CCP)6, excluding chronic pancreatitis secondary to benign ampullary stenosis7, cancer obstructing the main pancreatic duct8 9 and acute relapsing pancreatitis secondary to gallstones'0 radiological aspect of the main bile duct" is type I the most.common on September 25, 2021 by guest. Protected copyright. choledocus (Figure). This description has been repeatedly confirmed'2"13. It is a long stenosis of the intra- or retropancreatic part of the main bile duct.
    [Show full text]
  • An Update on the Management of Cholestatic Liver Diseases
    Clinical Medicine 2020 Vol 20, No 5: 513–6 CME: HEPATOLOGY An update on the management of cholestatic liver diseases Authors: Gautham AppannaA and Yiannis KallisB Cholestatic liver diseases are a challenging spectrum of autoantibodies though may be performed in cases of diagnostic conditions arising from damage to bile ducts, leading to doubt, suspected overlap syndrome or co-existent liver pathology build-up of bile acids and inflammatory processes that cause such as fatty liver. injury to cholangiocytes and hepatocytes. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are ABSTRACT the two most common cholestatic disorders. In this review we Key points detail the latest guidelines for the diagnosis and management of patients with these two conditions. Ursodeoxycholic acid can favourably alter the natural history of primary biliary cholangitis in a majority of patients, given at the appropriate dose of 13–15 mg/kg/day. Primary biliary cholangitis Primary biliary cholangitis (PBC) is a chronic autoimmune liver Risk stratification is of paramount importance in the disorder characterised by immune-mediated destruction of management of primary biliary cholangitis to identify epithelial cells lining the intrahepatic bile ducts, resulting in patients with suboptimal response to ursodeoxycholic acid persistent cholestasis and, in some patients, a progression to and poorer long-term prognosis. Alkaline phosphatase cirrhosis if left untreated. The exact mechanisms remain unclear >1.67 times the upper limit of normal and a bilirubin above but are most likely a result of exposure to environmental factors in the normal range indicate high-risk disease and suboptimal a genetically susceptible individual.1 The majority of patients are treatment response.
    [Show full text]
  • Guideline for the Evaluation of Cholestatic Jaundice
    CLINICAL GUIDELINES Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition ÃRima Fawaz, yUlrich Baumann, zUdeme Ekong, §Bjo¨rn Fischler, jjNedim Hadzic, ôCara L. Mack, #Vale´rie A. McLin, ÃÃJean P. Molleston, yyEzequiel Neimark, zzVicky L. Ng, and §§Saul J. Karpen ABSTRACT Cholestatic jaundice in infancy affects approximately 1 in every 2500 term PREAMBLE infants and is infrequently recognized by primary providers in the setting of holestatic jaundice in infancy is an uncommon but poten- physiologic jaundice. Cholestatic jaundice is always pathologic and indicates tially serious problem that indicates hepatobiliary dysfunc- hepatobiliary dysfunction. Early detection by the primary care physician and tion.C Early detection of cholestatic jaundice by the primary care timely referrals to the pediatric gastroenterologist/hepatologist are important physician and timely, accurate diagnosis by the pediatric gastro- contributors to optimal treatment and prognosis. The most common causes of enterologist are important for successful treatment and an optimal cholestatic jaundice in the first months of life are biliary atresia (25%–40%) prognosis. The Cholestasis Guideline Committee consisted of 11 followed by an expanding list of monogenic disorders (25%), along with many members of 2 professional societies: the North American Society unknown or multifactorial (eg, parenteral nutrition-related) causes, each of for Gastroenterology, Hepatology and Nutrition, and the European which may have time-sensitive and distinct treatment plans. Thus, these Society for Gastroenterology, Hepatology and Nutrition. This guidelines can have an essential role for the evaluation of neonatal cholestasis committee has responded to a need in pediatrics and developed to optimize care.
    [Show full text]
  • Diagnosis and Management of Primary Sclerosing Cholangitis
    AASLD PRACTICE GUIDELINES Diagnosis and Management of Primary Sclerosing Cholangitis Roger Chapman,1 Johan Fevery,2 Anthony Kalloo,3 David M. Nagorney,4 Kirsten Muri Boberg,5 Benjamin Shneider,6 and Gregory J. Gores7 Preamble classification used by the Grading of Recommendation This guideline has been approved by the American Asso- Assessment, Development, and Evaluation (GRADE) ciation for the Study of Liver Diseases and represents the workgroup with minor modifications (Table 1).3 The position of the Association. These recommendations pro- strength of recommendations in the GRADE system are vide a data-supported approach. They are based on the classified as strong (class 1) or weak (class 2). The quality following: (1) formal review and analysis of the recently- of evidence supporting strong or weak recommendations published world literature on the topic (Medline search); is designated by one of three levels: high (level A), mod- (2) American College of Physicians Manual for Assessing erate (level B), or low-quality (level C). Health Practices and Designing Practice Guidelines1; (3) guideline policies, including the AASLD Policy on the Definition and Diagnosis Development and Use of Practice Guidelines and the Definitions. Primary sclerosing cholangitis (PSC) is a American Gastroenterological Association Policy State- chronic, cholestatic liver disease characterized by inflam- ment on Guidelines2; and (4) the experience of the au- mation and fibrosis of both intrahepatic and extrahepatic thors in the specified topic. bile ducts,4 leading to the formation of multifocal bile Intended for use by physicians, these recommenda- duct strictures. PSC is likely an immune mediated, pro- tions suggest preferred approaches to the diagnostic, ther- gressive disorder that eventually develops into cirrhosis, apeutic and preventative aspects of care.
    [Show full text]
  • Cholestasis in Pediatrics
    Review articles Cholestasis in Pediatrics Mónica D’Amato G., MD,1 Patricia Ruiz N., MD,2 Karen Aguirre R., MD.,2 Susana Gómez Rojas, MD.3 1 General Practitioner, Pediatrics Resident at the Abstract Universidad Pontificia Bolivariana in Medellín Colombia Cholestasis always indicates a pathological process that can result in chronic liver dysfunction, the necessity 2 Pediatric Gastro-hepatologist at Pablo Tobón Uribe of liver transplantation and even death. (1) Cholestasis is a process in which there is a decrease in biliary Hospital in Medellín, Colombia flow, histological evidence of deposition of bile pigments in hepatocytes and bile ducts, and an increase in the 3 Pediatrics Resident at the Universidad Militar Nueva Granada in Bogotá, Colombia serum concentrations of products excreted in bile. Cholestasis can occur at any age. It is caused by alteration of the formation of bile by the hepatocytes or by obstruction of the flow in the intrahepatic or extrahepatic biliary ......................................... tracts. Neonatal cholestasis occurs in the first (3) months of life with elevated serum levels of direct bilirubin, Received: 14-01-16 Accepted: 01-11-16 cholesterol and bile acids. (2) In our environment, the most frequent cause is idiopathic neonatal hepatitis, followed by infectious causes. Obstructive causes have the worst prognoses. Among them, the most common is biliary atresia in which progressive obliteration of the extra hepatic biliary tract, parenchymal damage and intrahepatic biliary tract cause cirrhosis and death before the patient reaches three years of age. (1-3) The prognosis improves with surgical management if it is performed within the first 45 to 60 days of life.
    [Show full text]
  • Biliary Tract Obstruction in Chronic Pancreatitis
    HPB, 2007; 9: 421Á428 REVIEW ARTICLE Biliary tract obstruction in chronic pancreatitis ABDUL A. ABDALLAH1, JAKE E. J. KRIGE2 & PHILIPPUS C. BORNMAN2 1Department of Surgery, Aga Khan University Hospital, Nairobi, Kenya and 2Department of Surgery, University of Cape Town Health Sciences Faculty, and Surgical Gastroenterology Unit, Groote Schuur Hospital, Observatory 7925, Cape Town, South Africa Abstract Bile duct strictures are a common complication in patients with advanced chronic pancreatitis and have a variable clinical presentation ranging from an incidental finding to overt jaundice and cholangitis. The diagnosis is mostly made during investigations for abdominal pain but jaundice may be the initial clinical presentation. The jaundice is typically transient but may be recurrent with a small risk of secondary biliary cirrhosis in longstanding cases. The management of a bile duct stricture is conservative in patients in whom it is an incidental finding as the risk of secondary biliary cirrhosis is negligible. Initial conservative treatment is advised in patients who present with jaundice as most will resolve once the acute on chronic attack has subsided. A surgical biliary drainage is indicated when there is persistent jaundice for more than one month or if complicated by secondary gallstones or cholangitis. The biliary drainage procedure of choice is a choledocho-jejunostomy which may be combined with a pancreaticojejunostomy in patients who have associated pain. Since many patients with chronic pancreatitis have an inflammatory mass in the head of the pancreas, a Frey procedure is indicated but a resection should be performed when there is concern about a malignancy. Temporary endoscopic stenting is reserved for cholangitis while an expandable metal stent may be indicated in patients with severe co-morbid disease.
    [Show full text]
  • Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases 1 2 3 4 5 Keith D
    | PRACTICE GUIDANCE HEPATOLOGY, VOL. 0, NO. 0, 2018 Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases 1 2 3 4 5 Keith D. Lindor, Christopher L. Bowlus, James Boyer, Cynthia Levy, and Marlyn Mayo Intended for use by health care providers, this guid- Preamble ance identifies preferred approaches to the diagnostic This American Association for the Study of and therapeutic aspects of care for patients with PBC. Liver Diseases (AASLD) 2018 Practice Guidance As with clinical practice guidelines, it provides gen- on Primary Biliary Cholangitis (PBC) is an update eral guidance to optimize the care of the majority of of the PBC guidelines published in 2009. The 2018 patients and should not replace clinical judgment for updated guidance on PBC includes updates on etiol- a unique patient. ogy and diagnosis, role of imaging, clinical manifesta- The major changes from the last guideline to this tions, and treatment of PBC since 2009. The AASLD guidance include information about obeticholic acid 2018 PBC Guidance provides a data-supported (OCA) and the adaptation of the guidance format. approach to screening, diagnosis, and clinical man- agement of patients with PBC. It differs from more recent AASLD practice guidelines, which are sup- Etiology of Primary Biliary ported by systematic reviews and a multidisciplinary panel of experts that rates the quality (level) of the Cholangitis evidence and the strength of each recommendation Primary Biliary Cholangitis (PBC) is considered using the Grading of Recommendations Assessment, an autoimmune disease because of its hallmark sero- Development, and Evaluation system. In contrast, this logic signature, antimitochondrial antibody (AMA), (1-4) guidance was developed by consensus of an expert and specific bile duct pathology.
    [Show full text]
  • The Gut-Liver Axis in Cholestatic Liver Diseases
    nutrients Review The Gut-Liver Axis in Cholestatic Liver Diseases Andreas Blesl 1,* and Vanessa Stadlbauer 1,2 1 Division for Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria; [email protected] 2 Center for Biomarker Research in Medicine (CBmed), 8010 Graz, Austria * Correspondence: [email protected] Abstract: The gut-liver axis describes the physiological interplay between the gut and the liver and has important implications for the maintenance of health. Disruptions of this equilibrium are an important factor in the evolution and progression of many liver diseases. The composition of the gut microbiome, the gut barrier, bacterial translocation, and bile acid metabolism are the key features of this cycle. Chronic cholestatic liver diseases include primary sclerosing cholangitis, the generic term secondary sclerosing cholangitis implying the disease secondary sclerosing cholangitis in critically ill patients and primary biliary cirrhosis. Pathophysiology of these diseases is not fully understood but seems to be multifactorial. Knowledge about the alterations of the gut-liver axis influencing the pathogenesis and the outcome of these diseases has considerably increased. Therefore, this review aims to describe the function of the healthy gut-liver axis and to sum up the pathological changes in these cholestatic liver diseases. The review compromises the actual level of knowledge about the gut microbiome (including the mycobiome and the virome), the gut barrier and the consequences of increased gut permeability, the effects of bacterial translocation, and the influence of bile acid composition and pool size in chronic cholestatic liver diseases. Furthermore, therapeutic implications and future scientific objectives are outlined.
    [Show full text]
  • Conservative Management of Cholestasis with and Without Fever in Acute Biliary Pancreatitis
    Online Submissions: http://www.wjgnet.com/1948-9366office World J Gastrointest Surg 2012 March 27; 4(3): 55-61 [email protected] ISSN 1948-9366 (online) doi:10.4240/wjgs.v4.i3.55 © 2012 Baishideng. All rights reserved. OBSERVATION Conservative management of cholestasis with and without fever in acute biliary pancreatitis José Sebastião Santos, Rafael Kemp, José Celso Ardengh, Jorge Elias Jr José Sebastião Santos, Rafael Kemp, José Celso Ardengh, access to the treatment of local and systemic inflamma- Division of Digestive Surgery, Department of Surgery and Anat- tory/infectious effects of ABP with cholestasis and fever, omy, Faculty of Medicine of Ribeirão Preto, University of São and to characterize the possible scenarios and the sub- Paulo, CEP 14049-900 São Paulo, Brazil sequent approaches to the common bile duct, directed Jorge Elias Jr, Department of Internal Medicine, Faculty of Med- by less invasive examinations such as MRC or EUS. icine of Ribeirão Preto, University of São Paulo, CEP 14049-900 São Paulo, Brazil © 2012 Baishideng. All rights reserved. Author contributions: All the authors contributed to this paper. Supported by Fundação Waldemar Barnsley Pessoa Correspondence to: José Sebastião Santos, PhD, Professor Key words: Biliary pancreatitis; Cholestasis; Endoscopic of Digestive Surgery of the Medical School, University of São sphincterotomy; Cholangitis; Mortality; Magnetic reso- Paulo, Ribeirão Preto, CEP 14049-900 São Paulo, nance cholangiopancreatography; Endoscopic retro- Brazil. [email protected] grade cholangiography; Endoscopic ultrasonography; Telephone: +55-16-36022508 Fax: +55-16-36330836 Intensive care; Health system regulation Received: January 15, 2011 Revised: December 31, 2011 Accepted: January 10, 2012 Peer reviewer: Calogero Iacono, MD, Professor, Department of Published online: March 27, 2012 Surgery, University Hospital “GB Rossi”, Verona 37134, Italy Santos JS, Kemp R, Ardengh JC, Elias Jr J.
    [Show full text]